Spontaneously hypertensive rats: Further evaluation of age-related memory performance and cholinergic marker expression

Journal of Psychiatry and Neuroscience

Volumn 28, Issue 3, 2003, Pages 197-209

  Hernandez, Caterina M ^a   Høifødt, Helga ^b   Terry Jr , Alvin V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Acetylcholine; Aging; Animal; Cholinergic; Hypertension; Memory disorders; Models; Rats, inbred SHR; Rats, inbred WKY; Receptors

Indexed keywords

ACETYLCHOLINE; CHOLINE ACETYLTRANSFERASE; EPIBATIDINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; NICOTINIC RECEPTOR; PIRENZEPINE; RADIOLIGAND; TRITIUM; BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR; DIAGNOSTIC AGENT; FUSED HETEROCYCLIC RINGS; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC AGENT; PRESYNAPTIC RECEPTOR; PYRIDINE DERIVATIVE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD PRESSURE MONITORING; BRAIN TISSUE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; EVALUATION; FRONTAL CORTEX; IMMUNOBLOTTING; LIGAND BINDING; MALE; MAZE TEST; NONHUMAN; PHYSICAL PERFORMANCE; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PUTAMEN; RAT; RECEPTOR BINDING; STATISTICAL ANALYSIS; SUPERIOR COLLICULUS; WORKING MEMORY; ANIMAL; BINDING SITE; BRAIN; DISEASE MODEL; HYPERTENSION; MEMORY DISORDER; METABOLISM; PHYSIOLOGY; WISTAR RAT;

AGING; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; BIOLOGICAL MARKERS; BRAIN; DISEASE MODELS, ANIMAL; HYPERTENSION; IMMUNOBLOTTING; MALE; MAZE LEARNING; MEMORY DISORDERS; MUSCARINIC ANTAGONISTS; NICOTINIC AGONISTS; PIRENZEPINE; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC; RECEPTORS, PRESYNAPTIC;

EID: 0037831127     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993;138:353-64.
2. Launer LJ, Masaki K, Petrovich H, Foley D, Havlik RJ. The association between midlife blood pressure level and late-life cognitive function: the Honolulu-Asia Aging Study. JAMA 1995;274:1846-51.
3. Hebert R, Lindsay J, Verreault R, Rockwood K, Hill G, Dubois MF. Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke 2000;31:1487-93.
4. Breteler MMB. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153-60.
5. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5.
6. Akashi T, Arima K, Maruyama N, Ando S, Inose T. Severe cerebral atrophy in progressive supranuclear palsy: a case report. Clin Neuropathol 1989;9:195-9.
7. Ghika J, Bogousslavsky J. presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy. Arch Neurol 1997;54:1104-8.
8. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000;15(10):911-6.
9. Petrovich H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Neurobiol Aging 2000;21:57-62.
10. Meneses A, Hong E. Spontaneously hypertensive rats: a potential model to identify drugs for treatment of learning disorders. Hypertension 1998;31:968-72.
11. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 2000;24:31-9.
12. Knardahl S, Karlsen K. Passive-avoidance behavior of spontaneously hypertensive rats. Behav Neural Biol 1984;42:9-22.
13. Sutterer JR, Devito WJ, Rykaszewski I. Developmental aspect of 2-way shuttle box avoidance in the spontaneously hypertensive rat and normotensive rat. Dev Psychobiol 1981;14:405-14.
14. Sutterer JR, Perry J, Devito W. Two-way shuttlebox avoidance in the spontaneously hypertensive and normotensive rat. J Comp Physiol Psychol 1980;94:155-63.
15. Mori S, Kato M, Fujishima M. Impaired maze learning and cerebral glucose utilization in aged hypertensive rats. Hypertension 1995;25:545-53.
16. Nakamura-Palacios EM, Caldas CK, Fiorini A, Chagas KD, Chagas KD, Vasquez ED. Deficits of spatial learning and working memory in spontaneously hypertensive rats. Behav Brain Res 1996;74:217-21.
17. Wyss JM, Fisk G, van Groen T. Impaired learning and memory in mature spontaneously hypertensive rats. Brain Res 1992;592:135-40.
18. Gattu M, Pauly JR, Boss KL, Summers JB, Buccafusco JJ. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors I. Brain Res 1997;771:89-103.
19. Gattu M, Terry AV, Pauly JR, Buccafusco JJ. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors II. Brain Res 1997;771:104-14.
20. Terry AV, Hernandez CM, Buccafusco JJ, Gattu M. Deficits in spatial learning and nicotinic-acetylcholine receptors in older, spontaneously hypertensive rats. Neurosci 2000;101:357-68.
21. Sabbatini M, Catalani A, Consoli C, Marletta N, Tomassoni D, Avola R. The hippocampus in spontaneously hypertensive rats: an animal model of vascular dementia? Mech Ageing Dev 2002;123:547-59.
22. Sabbatini M, Strocchi P, Vitaioli L, Amenta F. The hippocampus in spontaneously hypertensive rats: a quantitative microanatomical study. Neurosci 2000;100:251-8.
23. Linz W, Jessen T, Becker BA, Schoelkens BA, Wiemer G. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation 1997;96:3164-72.
24. Linz W, Wohlfart P, Schoelkens BA, Becker RHA, Malinski T, Wiemer G. Late treatment with ramipril increases survival in old spontaneously hypertensive rats. Hypertension 1999;34:291-5.
25. Okamoto K, editor. Spontaneous hypertension: its pathogenesis and complications. New York: Springer-Verlag; 1972.
26. Muir JL. Acetylcholine, aging, and Alzheimer's disease. Pharmacol Biochem Behav 1997;56:687-96.
27. Taylor L, Griffith WH. Age-related decline in cholinergic synaptic transmission in hippocampus. Neurobiol Aging 1993;14(5):509-15.
28. Bowen DM, Benton JS, Spillane JA, Smith CC, Allen SJ. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci 1982;57(2-3):191-202.
29. Efange SMN, Garland EM, Staley JK, Share AB, Mash DC. Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol Aging 1997;18:407-13.
30. 3H] Vesamicol binding in human brain cholinergic deficiency disorders. Neurosci Lett 1990;177:347-52.
31. Bartus RT. On neurodegenerative diseases, models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000;63:495-529.
32. 3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease. Neurosci 1999;94:685-96.
33. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia 1994;5:163-7.
34. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer's type dementia. J Neural Transm 1996;103:1211-20.
35. Wallin A, Blennow K, Gottfries CG. Neurochemical abnormalities in vascular dementia. Dementia 1989;1:120-30.
36. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet 2002;359:1283-90.
37. Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (ReminylTM). Int J CIin Prac 2001;120:24-8.
38. McNamara RK, Skelton RW. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Rev 1993;18:33-49.
39. Oda Y. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int 1999;49:921-37.
40. Roghani A, Shirzadi A, Butcher LL, Edwards RH. Distribution of the vesicular transporter for acetylcholine in the rat central nervous system. Neurosci 1998;82:195-212.
41. Marks MJ, Smith KW, Collins AC. Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. J Pharmacol Exp Ther 1998;285:377-86.
42. Paxinos G, Watson CR. Rat brain in stereotaxic coordinates. 4th ed. San Diego (CA): Academic Press; 1998.
43. Gattu M, Pauly JR, Urbanawiz S, Buccafusco JJ. Autoradiographic comparison of muscarinic M1 and M2 binding sites in the CNS of spontaneously hypertensive and normotensive rats. Brain Res 1997;771:173-83.
44. Pare WP. Investigatory behavior of a novel conspecific by Wistar-Kyoto, Wistar and Sprague-Dawley rats. Brain Res Bull 2000;53:759-65.
45. Durand M, Berton O, Aguerre S, Edno L, Combourieu I, Mormede P, et al. Effects of repeated fluoxetine on anxietyrelated behaviours, central serotonergic, and the corticotropic axis in SHR and WKY rats. Neuropharmacology 1999;38(6):893-907.
46. Kulikov A, Aguerre S, Berton O, Ramos A, Mormede P, Chaouloff F. Central sertonergic systems in the spontaneously hypertensive and Lewis rat strains that differ in the elevated plus-maze test of anxiety. J Pharmacol Exp Ther 1997;281:775-84.
47. Russell VA, Wiggins TM. Increased glutamate-stimulated norepinephrine release from prefrontal cortex slices of spontaneously hypertensive rats. Metab Brain Dis 2000;15:294-304.
48. Russell VA. The nucleus accumbens motor-limbic interface of the spontaneously hypertensive rat as studied in vitro by the superfusion slice technique. Neurosci Biobehav Rev 2000;24:133-6.
49. Meneses A, Castillo C, Ibarra M, Hong, E. Effects of aging and hypertension on learning, memory and activity in rats. Physiol Behav 1996;60:341-5.
50. Blokland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res Rev 1996;21:285-300.
51. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998;39:89-105.
52. van der Zee EA, Luiten PGM. Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. Prog Neurobiol 1999;58:409-71.
53. Caufield MP. Muscarinic receptors - characterization, coupling and function. Pharmacol Ther 1993;58:319-79.
54. Flynn DD, Ferrari-DiLeo G, Levey AI, Mash DC. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci 1995;56:869-76.
55. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995;64:1888-91.
56. Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SR. Neuronal nicotinic receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 2001;92:89-108.
57. Zoli M, Lena C, Picciotto MR, Changeux Jp. Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J Neurosci 1998;18(12):4461-72.
58. White P, Hiley DR, Goodhardt MJ, Carrasco LH, Keet JP, Williams IE, et al. Neocortical cholinergic neurons in elderly people. Lancet 1977;1(8013):668-71.
59. Shiozaki K, Iseki E, Uchiyama H, Watanebe Y, Haga T, Kameyama K, et al. Alternations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry 2000;68:253-4.
60. Binns KE, Salt TE. The functional influence of nicotinic cholinergic receptors on the visual responses of neurons in the superficial superior colliculus. Vis Neurosci 2000;17(2):283-9.
61. Parsons SM, Prior C, Marshall IG. Acetylcholine transport, storage, and release. Int Rev Neurobiol 1993;35:279-390.